Correspondence 0001193125-25-020014 from Sionna Therapeutics, Inc. (SION) (CIK 0002036042) (SION)
Sionna Therapeutics, Inc. (SION) (CIK 0002036042)
Date: Feb. 4, 2025 · CIK: 0002036042 · Accession: 0001193125-25-020014
AI Filing Summary & Sentiment
File numbers found in text: 333-284352
Letter
February 4, 2025
VIA EDGAR AND EMAIL
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention: Tamika Sheppard, Laura Crotty, Jenn Do and Angela Connell
Re: Sionna Therapeutics, Inc. (the “Company”)
Registration Statement on Form S-1
File No. 333-284352
Ladies and Gentleman:
In connection with the above-referenced Registration Statement, we wish to advise you that between February 3, 2025 and the date hereof, we effected the distribution of approximately 3,882 copies of the Company’s Preliminary Prospectus dated February 3, 2025 to prospective underwriters, institutional investors, prospective dealers, brokers, individuals, rating agencies and others.
We have complied and will comply and have been informed by the other participating underwriters that they have complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
As Representatives of the several underwriters, we hereby join in the request of the Company that the effectiveness of the above-referenced Registration Statement, as amended, be accelerated to 4:01 p.m., Eastern Time, on February 6, 2025, or as soon thereafter as practicable.
[Signature Page Follows]
Very truly yours,
GOLDMAN SACHS & CO. LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP February 4, 2025 VIA EDGAR AND EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Tamika Sheppard, Laura Crotty, Jenn Do and Angela Connell Re: Sionna Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-284352 Ladies and Gentleman: In connection with the above-referenced Registration Statement, we wish to advise you that between February 3, 2025 and the date hereof, we effected the distribution of approximately 3,882 copies of the Company’s Preliminary Prospectus dated February 3, 2025 to prospective underwriters, institutional investors, prospective dealers, brokers, individuals, rating agencies and others. We have complied and will comply and have been informed by the other participating underwriters that they have complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. As Representatives of the several underwriters, we hereby join in the request of the Company that the effectiveness of the above-referenced Registration Statement, as amended, be accelerated to 4:01 p.m., Eastern Time, on February 6, 2025, or as soon thereafter as practicable. [Signature Page Follows] Very truly yours, GOLDMAN SACHS & CO. LLC TD SECURITIES (USA) LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters GOLDMAN SACHS & CO. LLC By: /s/ Ryan Fisk Name: Ryan Fisk Title: Managing Director TD SECURITIES (USA) LLC By: /s/ Mariel Healy Name: Mariel Healy Title: Managing Director STIFEL, NICOLAUS & COMPANY, INCORPORATED By: /s/ Ken Clausman Name: Ken Clausman Title: Managing Director GUGGENHEIM SECURITIES, LLC By: /s/ Thomas Burkly Name: Thomas Burkly Title: Senior Managing Director [Signature Page to Request for Acceleration of Effectiveness]